July 15, 2016Chemical Research in Toxicology
Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines
Key result
Pixantrone is a distinct drug for refractory or relapsed non-Hodgkin's lymphoma that avoids the cardiotoxicity of traditional anthracyclines through unique pharmacological mechanisms.
Why the study?
Does pixantrone provide antitumor activity with reduced cardiotoxicity compared to anthracyclines in patients with refractory or relapsed non-Hodgkin's lymphoma?
Population
Patients with refractory or relapsed non-Hodgkin's lymphoma (NHL) and preclinical laboratory animal models
Comparison
Pixantrone vs Anthracyclines (e.g., doxorubicin) or mitoxantrone
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Enables anthracycline-like therapy in cardiotoxicity-vulnerable NHL patients; extends class options in late-phase trials.
Structured PICO
Does pixantrone provide antitumor activity with reduced cardiotoxicity compared to anthracyclines in patients with refractory or relapsed non-Hodgkin's lymphoma?
P
Population
Patients with refractory or relapsed non-Hodgkin's lymphoma (NHL) and preclinical laboratory animal models
I
Intervention
Pixantrone
C
Comparator
Anthracyclines (e.g., doxorubicin) or mitoxantrone
O
Outcome
Antitumor activity and cardiotoxicity
Pixantrone is a distinct drug from traditional anthracyclines, offering a therapeutic option for refractory/relapsed NHL with a favorable cardiac safety profile, even in patients with prior anthracycline exposure.
Cite This Study
Menna et al. (2016) conducted a review in Refractory or relapsed non-Hodgkin's lymphoma (NHL). Pixantrone vs. Anthracyclines or mitoxantrone was evaluated. Pixantrone is a distinct drug for refractory or relapsed non-Hodgkin's lymphoma that avoids the cardiotoxicity of traditional anthracyclines through unique pharmacological mechanisms.